好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Smartphone-Mediated At-Home Telespirometry Erect and Supine Slow Vital Capacity Decline Differences Based On NIV Status in Subjects With ALS
General Neurology
P8 - Poster Session 8 (8:00 AM-9:00 AM)
2-004
Measure erect and supine slow vital capacity (eSVC/sSVC) every two weeks via at-home telespirometry (AHT) in subjects with ALS between quarterly eSVC/sSVC assessments in a prospective, longitudinal, observational clinical study [NCT05106569] with the ZEPHYRx® Remote Respiratory Monitoring™ dashboard and MIR’s Spirobank Smart Spirometer connected to the Breathe Easy application.

AHT aims to provide earlier treatment of ALS-associated respiratory comorbidities. This first implementation study assessed eSVC/sSVC longitudinally in subjects with ALS in the home between clinic visits.
eSVC/sSVC were measured via conventional spirometery during quarterly in-clinic assessments (baseline, 12, 24 weeks) and via AHT at two-week intervals in the home with respiratory therapist supervision for each subject/caregiver. Real-time respiratory data from subject’s smartphone was accessible on a dashboard for pulmonologist review and RedCap database download. Validity between conventional and portable spirometers and subject repeatability were completed. The random effects linear model analyzed eSVC/sSVC change.
Subjects (n=98): ALS diagnosis age (standard deviation [SD])=62.6 (10.4) years; disease duration (SD)=0.8 (1.8) years; ALSFRS-Rtotal (SD)=33.3 (7.6); eSVC baseline (SD)=72.6 (21.7) %predicted (%p); non-invasive ventilation (NIV)baseline=19; NIVstarted post-baseline=38; NIVnon-user=41. Most (72.5%) subjects completed ≥6 AHT. Monthly decline rate for eSVC (−1.75 %p/month, P<0.001) and sSVC (−1.12 %p/month, P<0.001) of NIV non-users was statistically significantly different from monthly decline rate for eSVC (−3.10 %p/month) and sSVC (−3.31 %p/month) for subjects who started NIV after baseline. Monthly decline rate for eSVC (−1.25 %p/month) and sSVC (−1.00 %p/month) for subjects on NIV at baseline was not statistically different from NIV non-users.
This first implementation study of smartphone application-mediated AHT eSVC/sSVC measurement suggests statistically significant differences in monthly decline between NIV non-users and subjects on NIV at baseline vs subjects who started NIV post-baseline. Ongoing within-group analysis of the latter cohort of NIV adopters aims to determine when monthly decline rate decreases with NIV initiation.
Authors/Disclosures
Eufrosina I. Young, MD (Upstate University Hospital)
PRESENTER 		The institution of Dr. Young has received research support from Mitsubishi Tanabe Pharma America.
Dongliang Wang Dongliang Wang has nothing to disclose.
George P. Slavinski, Respiratory Therapist (SUNY Upstate Medical University) Mr. Slavinski has nothing to disclose.
Dragos Manta Dragos Manta has nothing to disclose.
Birendra Sah (Upstate Medical University) Birendra Sah has received publishing royalties from a publication relating to health care.
Urvi G. Desai, MD, FAAN (Dept of Neurology, CMC) Dr. Desai has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Desai has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fulcrum. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenx.
Lena Deb (SUNY Upstate Medical University) Lena Deb has nothing to disclose.
Marielle Posmik Marielle Posmik has nothing to disclose.
Jeffrey P. Collins, RN Mr. Collins has nothing to disclose.
Emma Blystone, MS Ms. Blystone has nothing to disclose.
Jenny Meyer, MD (Upstate Medical University) The institution of Dr. Meyer has received research support from Grifols. The institution of Dr. Meyer has received research support from Medicinova.
Bhavya Narapureddy, MBBS (Upstate Medical University) Dr. Narapureddy has nothing to disclose.
Ahmed Ibrahim, MBBCH (Mayo Clinic) Dr. Ibrahim has nothing to disclose.
Grace Marie N. Dominguez, MD Dr. Dominguez has nothing to disclose.
Darshana Vijaywargiya, MBBS Dr. Vijaywargiya has nothing to disclose.
Sara Abdelhafiz, MBBS Dr. Abdelhafiz has nothing to disclose.
Pradeep Chevula, MD (17 Presidential Cts) Dr. Chevula has nothing to disclose.
Takuya Kudo (Mitsubishi Tanabe Pharma America, Inc.) Mr. Kudo has nothing to disclose.
Kinjal Patel Kinjal Patel has nothing to disclose.
Stephen Apple Stephen Apple has received personal compensation for serving as an employee of Mitsubishi Tanabe Pharma America, Inc.
Benjamin R. Brooks, MD, FAAN (Clinical Trials Planning LLC) Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with 好色先生 that is relevant to AAN interests or activities.